The 197-patient study also identified several potential biomarkers for use in future studies

The 105-patient study will involve two parts: Part A will treat 15 subjects with ADX71149 as a monotherapy, while Part B will test the drug as an add-on therapy in 90 subjects with residual positive symptoms or predominant negative symptoms or in subjects with insufficient response to clozapine

VentiRx Pharmaceuticals Inc., of San Diego, reported results from an 80-patient study showing that its VTX-1463, a Toll-like receptor 8 agonist, demonstrated statistically significant improvements in allergy symptoms compared to placebo

Kythera Biopharmaceuticals Inc., of Los Angeles, reported additional efficacy data from a third Phase III study of ATX-101, an adipolytic agent aimed at reducing submental fat (SMF), with results showing a statistically significant difference for the 2 mg/cm2 dose relative to placebo for all Patient-Reported Submental Fat Impact Scale (PR-SMFIS) measures, as well as a composite PR-SMFIS score (p < 0.05.) The firm previously reported initial data from the 129-patient study showing statistically

The 68-patient study is designed to inform the plans for two pivotal Phase III studies and is not designed itself to demonstrate statistical differentiation from vehicle

The 121-patient study was designed to assess three different doses of the once-monthly version vs. Bydureon

The firm anticipates reporting data from the 30-patient study in the third quarter

The 60-patient study was funded by the National Institutes of Health and other foundations

At week eight, 70 percent of patients in the study showed a clinical response, defined as a decline in CDAI of 70 points or more, and half were in clinical remission

Pharming expects to enroll 50 patients in the study, which may provide additional data in support of FDA approval for Rhucin at the 50 U/kg dose

Results from the 80-patient study showed that 54 percent of diabetic wounds in the intent-to-treat population receiving the high dose of DSC127 achieved 100 percent closure in 12 weeks or less, compared with 33 percent of patients receiving placebo control and 30 percent of patients receiving the low dose of DSC127

The 350-patient study showed that vaccination with Imvamune was well tolerated, and subjects with atopic dermatitis generated strong vaccinia-specific immune responses similar to healthy subjects

Anadys expects to enroll approximately 275 patients in the study, with the primary endpoint of sustained virological response 24 weeks after patients complete treatment

Data from the 70-patient study also showed no serious side effects

The 48-patient study showed no severe adverse events and low transdermal absorption of topical RK-023 from the scalp

The firm previously reported that the 190-patient study had achieved its primary endpoint of a reduction in 28-day all-cause mortality

The 250-patient study will test the next-generation purine nucleoside phosphorylase inhibitor in combination with allopurinol in subjects who have failed to reach the serum uric acid objective of < 6 mg/dL following treatment with allopurinol 300 mg alone

The 1,217-patient study showed that 71.5 percent of patients in the Rituxan group achieved complete or unconfirmed complete responses after two years vs. 52.5 percent in the observation group

The 702-patient study is testing the percent change in triglyceride level from baseline to week 12 as the primary endpoint